These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31728936)

  • 1. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
    Agnihotri G; Shi K; Lio PA
    Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dupilumab-related blepharoconjunctivitis: Recommendations of the CEDRE group. Atopic dermatitis, conjunctivitis and dupilumab: Which management approach?].
    Doan S; Arnould L; Febvay C; Fournié P; Gueudry J; Labalette P; Ouilhon C; Tran TH; Vabres B; Barbarot S; Bouaziz JD; Du-Thanh A; Jachiet M; Seneschal J; Soria A; Staumont-Sallé D; Baudouin C; Mortemousque B
    J Fr Ophtalmol; 2022 Mar; 45(3):277-287. PubMed ID: 35078645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
    Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
    J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Conjunctivitis for the Dermatologist.
    Gooderham M; McDonald J; Papp K
    J Cutan Med Surg; 2018; 22(2):200-206. PubMed ID: 29191053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
    Wu D; Daniel BS; Lai AJX; Wong N; Lim DKA; Murrell DF; Lim BXH; Mehta JS; Lim CHL
    Surv Ophthalmol; 2022; 67(5):1419-1442. PubMed ID: 35181280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
    Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
    J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
    Hayama K; Fujita H
    Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
    [No Abstract]   [Full Text] [Related]  

  • 16. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
    Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine 0.1% (Ikervis
    Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.
    Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S
    Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.